Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
Moleculin BiotechEli Lilly
Last price
$0.27$1,427.28
Currency
USD
USD
$7.9M$1.3T
-46.65
-$191.95$30.81
2.000.39
0$6.69
00.48%
Sector
HealthHealth
Employees
1750,000
Ticker
$MBRX.O$LLY
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $MBRX.O or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.